The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, raised $113 million by offering 7.5 million shares at $15, within the range of $14 to $16. The company offered 0.5 million more shares than anticipated. ...read more
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to...read more
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Immuneering's oncology programs target mutations of the MAPK...read more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Oncology biotech Immuneering prices upsized IPO at $15 midpoint
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, raised $113 million by offering 7.5 million shares at $15, within the range of $14 to $16. The company offered 0.5 million more shares than anticipated. ...read more
Oncology biotech Immuneering sets terms for $105 million IPO
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to...read more
Oncology biotech Immuneering files for a $100 million IPO
Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Immuneering's oncology programs target mutations of the MAPK...read more